The Helios Alliance Applauds Dr. Rahul Gupta's Appointment to Knoa Foundation Board of Trustees

The Helios Alliance announced support for Dr. Rahul Gupta’s appointment to the Knoa Foundation Board of Trustees, effective May 7, 2026. Gupta, a member of The Helios Alliance Leadership Team, will oversee Knoa Pharma, a company formed after Purdue Pharma’s $7.4 billion opioid settlement. The settlement, involving 55 attorneys general, prohibits Knoa from marketing opioids and mandates independent monitoring to ensure safe distribution. Gupta previously led the White House Office of National Drug Control Policy from 2021 to 2025, coordinating a $44 billion budget and expanding naloxone access, which saved tens of thousands of lives. Currently, he serves as President of GATC Health, an AI-driven drug discovery company. The Helios Alliance highlighted Gupta’s expertise in policy, science, and crisis response, emphasizing his role in advancing accountability in opioid abatement. The Knoa Foundation, formed under the settlement, now owns Purdue Pharma’s manufacturing assets. Alabama Attorney General Steve Marshall, who collaborated with The Helios Alliance on opioid settlement frameworks, noted the state’s leadership in deploying funds responsibly. The Alliance’s Project RenewAL, a statewide initiative, aims to allocate settlement resources based on community needs, following a baseline assessment announced in March. The Knoa Foundation Board includes Dr. Paul Rothman, former Johns Hopkins School of Medicine CEO, and David Saltzman, co-founder of The Robin Hood Foundation. Gupta’s appointment aligns with Alabama’s goal to demonstrate effective opioid recovery strategies nationwide, leveraging settlement funds for long-term impact.